TNFSF10 and cancer: Having established that EV-T partially overcomes TRAIL-resistance of cancer cells, we next addressed the feasibility of using dinaciclib to boost its effect, since an increasing volume of data has demonstrated that combination therapy of dinaciclib with other drugs may promote therapeutic efficacy while reducing adverse side effects [20].